In this context, the aim of the current study was to obtain an effective PTX-based anti-tumor strategy targeting NLRP3 inflammasome using both pharmaceutical modulation assisted by ATP and MCC950 and gene silencing protocol using NLRP3 specific siRNA. The gene discussed is NLRP3; the disease is neoplasm.